HK1112236A1 - Piperazine-substituted benzothiophenes for treatment of mental disorders - Google Patents

Piperazine-substituted benzothiophenes for treatment of mental disorders

Info

Publication number
HK1112236A1
HK1112236A1 HK08107408.3A HK08107408A HK1112236A1 HK 1112236 A1 HK1112236 A1 HK 1112236A1 HK 08107408 A HK08107408 A HK 08107408A HK 1112236 A1 HK1112236 A1 HK 1112236A1
Authority
HK
Hong Kong
Prior art keywords
piperazine
treatment
mental disorders
substituted benzothiophenes
benzothiophenes
Prior art date
Application number
HK08107408.3A
Other languages
English (en)
Inventor
Hiroshi Yamashita
Jun Matsubara
Kunio Oshima
Hideaki Kuroda
Nobuaki Ito
Shin Miyamura
Satoshi Shimizu
Tatsuyoshi Tanaka
Haruka Takahashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645750&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1112236(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1112236A1 publication Critical patent/HK1112236A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08107408.3A 2005-04-14 2008-07-04 Piperazine-substituted benzothiophenes for treatment of mental disorders HK1112236A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005116698 2005-04-14
PCT/JP2006/308162 WO2006112464A1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders

Publications (1)

Publication Number Publication Date
HK1112236A1 true HK1112236A1 (en) 2008-08-29

Family

ID=36645750

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107408.3A HK1112236A1 (en) 2005-04-14 2008-07-04 Piperazine-substituted benzothiophenes for treatment of mental disorders

Country Status (27)

Country Link
US (14) US7888362B2 (de)
EP (1) EP1869025B3 (de)
KR (1) KR100937623B1 (de)
CN (1) CN101155804B (de)
AR (1) AR053577A1 (de)
AT (1) ATE496911T3 (de)
AU (1) AU2006237905C1 (de)
BR (1) BRPI0609785B8 (de)
CA (1) CA2602247C (de)
CY (2) CY1111206T1 (de)
DE (1) DE602006019838D1 (de)
DK (1) DK1869025T6 (de)
ES (1) ES2358631T7 (de)
HK (1) HK1112236A1 (de)
HU (2) HUE011611T6 (de)
IL (1) IL185909A (de)
IN (1) IN2012DN00855A (de)
LT (1) LTC1869025I2 (de)
LU (1) LUC00086I2 (de)
MY (1) MY142746A (de)
NL (1) NL300946I2 (de)
PL (1) PL1869025T6 (de)
PT (1) PT1869025E (de)
SI (1) SI1869025T1 (de)
TW (1) TWI320783B (de)
WO (1) WO2006112464A1 (de)
ZA (1) ZA200708686B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101157272B1 (ko) 2003-07-22 2012-06-15 아레나 파마슈티칼스, 인크. 5?ｈｔ2ａ 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP2018371B1 (de) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primäramine und derivate davon als modulatoren des 5-ht2a-serotonin-rezeptors zur behandlung damit zusammenhängender erkrankungen
WO2007136680A2 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
MY154962A (en) 2006-05-18 2015-08-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
TW200831498A (en) * 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
MX2010008778A (es) * 2008-02-15 2010-08-30 Hoffmann La Roche Derivados de 3-alquil-piperazina y usos de la misma.
TWI429643B (zh) 2008-02-22 2014-03-11 Actelion Pharmaceuticals Ltd 唑啶酮衍生物
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN104784173B (zh) 2008-10-28 2019-07-26 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
EP3309151A1 (de) 2009-06-25 2018-04-18 Alkermes Pharma Ireland Limited Heterocyclische verbindungen zur behandlung von neurologischen und psychologischen erkrankungen
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ603268A (en) 2010-05-04 2015-02-27 Alkermes Pharma Ireland Ltd Process for synthesizing oxidized lactam compounds
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EP2736894B1 (de) 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von benzo[b]thiophen-verbindungen
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JO3190B1 (ar) * 2011-10-19 2018-03-08 Otsuka Pharma Co Ltd محلول للتناول عن طريق الفم
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
CA2872883A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
EP2792359A1 (de) * 2013-04-19 2014-10-22 Merz Pharma GmbH & Co. KGaA Behandlung von L-DOPA-induzierter Dyskinesie mit OPC-14523 oder OPC-34712
KR101472916B1 (ko) 2013-06-27 2014-12-16 한국과학기술연구원 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN104557896A (zh) 2013-10-18 2015-04-29 沈敬山 布瑞哌唑、其关键中间体及其盐的制备方法
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
SG10201809280PA (en) 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
CN105985314A (zh) * 2015-02-05 2016-10-05 苏州旺山旺水生物医药有限公司 布瑞哌唑类似物的制备方法
CN104844586A (zh) * 2015-04-16 2015-08-19 重庆医药工业研究院有限责任公司 一种依匹哌唑无定型物及其制备方法
CN104829588B (zh) * 2015-04-30 2017-03-29 苏州苏旺森生物医药科技有限公司 一种苯并[b]噻吩的制备方法及其中间体
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
EP4119141A1 (de) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin zur prophylaxe und behandlung von schlafverhaltensstörungen in der rem-phase
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN105061414B (zh) * 2015-07-21 2019-01-01 杭州新博思生物医药有限公司 一锅法制备Brexpiprazole
WO2017025987A1 (en) 2015-08-11 2017-02-16 Mylan Laboratories Limited Process for the preparation of brexpiprazole
EP3150591A1 (de) 2015-10-02 2017-04-05 Crystal Pharma S.A.U Prozess und zwischenprodukte für die herstellung von benzo[b]thiophenverbindungen
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
CN105440026A (zh) * 2015-12-04 2016-03-30 上海勋和医药科技有限公司 依匹哌唑的制备方法
CN105461704A (zh) * 2015-12-15 2016-04-06 南京艾德凯腾生物医药有限责任公司 一种依匹哌唑的制备方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
CN106916148B (zh) * 2015-12-25 2021-07-06 上海科胜药物研发有限公司 一种合成依匹哌唑的方法
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
CN106938982A (zh) * 2016-01-05 2017-07-11 连云港皓海医药科技有限公司 布瑞哌唑的制备方法及用于制备布瑞哌唑的化合物
CN105399736B (zh) * 2016-01-07 2018-10-19 安徽省逸欣铭医药科技有限公司 一种依匹哌唑新的制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) * 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2017216661A1 (en) 2016-06-17 2017-12-21 Jubilant Generics Limited Process for the preparation of brexpiprazole from 7-(4-chlorobutoxy)quinolin-2(1h)-one and 1-(benzo[b]thiophen-4-yl)piperazine
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
EP3500249A1 (de) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmazeutische zusammensetzungen einer benzothiophenverbindung
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
WO2018060916A1 (en) * 2016-09-28 2018-04-05 Alembic Pharmaceuticals Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
WO2018087775A1 (en) * 2016-11-09 2018-05-17 Msn Laboratories Private Limited, R&D Center Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1h)-one
CN111233848A (zh) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
EP3577111A1 (de) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Kristallines brexpiprazol
WO2018172463A1 (en) 2017-03-22 2018-09-27 Amneal Pharmaceuticals Company Gmbh Process for the preparation of brexpiprazole
WO2019073481A1 (en) * 2017-10-12 2019-04-18 Indoco Remedies Limited PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND ITS INTERMEDIATES
SG11202005361RA (en) 2017-12-14 2020-07-29 H Lundbeck As Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3501506B1 (de) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablettenzusammensetzung mit brexpiprazol
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
EP3545950A1 (de) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmazeutische zusammensetzung, umfassend brexpiprazole
WO2019242717A1 (zh) * 2018-06-21 2019-12-26 中国科学院上海药物研究所 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
CN111320619A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物的杂质及用途
CN109970705B (zh) * 2019-05-14 2021-02-09 浙江工业大学 一种应用廉价金属铜制备依匹哌唑中间体及依匹哌唑的方法
JPWO2021029020A1 (de) * 2019-08-13 2021-02-18
EP4132646A1 (de) * 2020-04-08 2023-02-15 Remix Therapeutics Inc. Verbindungen und verfahren zur modulation des spleissens
CN116096715A (zh) * 2020-07-06 2023-05-09 泰科根公司 用于精神障碍或精神增强的有益苯并噻吩组合物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN114181202A (zh) * 2021-12-17 2022-03-15 湖南省湘中制药有限公司 一种依匹哌唑的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910955A (en) 1970-12-21 1975-10-07 Aspro Nicholas Ltd Benzothiophene-ethylamines
DK574274A (de) 1973-12-06 1975-07-28 Ciba Geigy Ag
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2827566A1 (de) 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS56164186A (en) 1980-05-21 1981-12-17 Otsuka Pharmaceut Co Ltd Carbostyril derivative
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
EP0189612B1 (de) 1984-12-21 1992-11-04 Duphar International Research B.V Arzneimittel mit psychotroper Wirkung
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
GB8704572D0 (en) 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
CA2157348A1 (en) 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DK0732332T3 (da) 1995-03-17 2002-04-15 Aventis Pharma Inc Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
KR100422850B1 (ko) 1995-09-15 2004-07-23 사노피-신델라보 세로토닌길항제로서의2(1h)-퀴놀론유도체
AU6859096A (en) 1995-09-22 1997-04-09 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
ATE340173T1 (de) 1996-03-29 2006-10-15 Duphar Int Res Piperazin- und piperidin- derivate
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP0934932A4 (de) 1996-08-22 2002-06-26 Meiji Seika Kaisha Chinolinderivate und psychotropes mittel
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
ATE253058T1 (de) * 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
ATE241341T1 (de) 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
CA2336117A1 (en) 1998-06-30 2000-01-06 Sidney Xi Liang Piperidine derivatives having effects on serotonin related systems
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
CA2716369C (en) 1999-05-24 2013-05-14 Mitsubishi Tanabe Pharma Corporation Phenoxypropylamine compounds
WO2001009126A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Serotonergic benzothiophenes
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
AU2251801A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
MXPA03006524A (es) 2001-02-16 2003-09-25 Aventis Pharma Inc Derivados heterociclicos novedosos de amidas y su uso como ligandos para receptor d3 de dopamina.
JP4310605B2 (ja) 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10151569A1 (de) 2001-10-23 2003-04-30 Basf Ag Thermisch härtbare Bindemittel
US20030153617A1 (en) 2001-12-18 2003-08-14 Dalen Frans Van Simvastatin dosage forms
BR0314393A (pt) 2002-09-17 2005-07-19 Warner Lambert Co Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
DE50308190D1 (de) 2002-09-20 2007-10-25 Osram Opto Semiconductors Gmbh Optischer abtastkopf und verfahren zur herstellung desselben
CA2500115A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
PT1575590E (pt) 2002-12-27 2007-12-06 Otsuka Pharma Co Ltd Derivados de carboestirilo e inibidores da reabsorção de serotonina para o tratamento de distúrbios de humor
EP1480953B2 (de) 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von aripiprazole
RS20050810A (en) 2003-04-29 2007-08-03 Pfizer Inc., 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
PL1626721T3 (pl) 2003-05-23 2017-05-31 Otsuka Pharmaceutical Co., Ltd. Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
GB0504203D0 (en) 2005-03-01 2005-04-06 Novartis Ag Organic compounds
ES2526415T3 (es) 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
ATE535243T1 (de) 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
US7968431B2 (en) 2008-07-15 2011-06-28 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
WO2010052727A1 (en) 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
EP2736894B1 (de) * 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von benzo[b]thiophen-verbindungen
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
US20200237755A1 (en) 2020-07-30
TWI320783B (en) 2010-02-21
PL1869025T3 (pl) 2011-06-30
US20170368060A1 (en) 2017-12-28
LTC1869025I2 (lt) 2019-05-10
DK1869025T6 (da) 2017-01-02
US7888362B2 (en) 2011-02-15
CY2018028I1 (el) 2019-07-10
TW200716619A (en) 2007-05-01
CA2602247A1 (en) 2006-10-26
CN101155804B (zh) 2013-03-27
PT1869025E (pt) 2011-02-04
HUS1800041I1 (hu) 2018-11-28
AU2006237905B2 (en) 2009-09-03
ES2358631T3 (es) 2011-05-12
KR100937623B1 (ko) 2010-01-20
ZA200708686B (en) 2009-01-28
US20140163039A1 (en) 2014-06-12
IL185909A (en) 2014-08-31
CA2602247C (en) 2013-04-02
LTPA2018509I1 (lt) 2018-09-10
ATE496911T3 (de) 2011-02-15
US20160051548A1 (en) 2016-02-25
AU2006237905C1 (en) 2015-11-19
MY142746A (en) 2010-12-31
US8349840B2 (en) 2013-01-08
BRPI0609785A2 (pt) 2010-04-27
US20190321359A1 (en) 2019-10-24
DE602006019838D1 (de) 2011-03-10
EP1869025B3 (de) 2016-08-31
IL185909A0 (en) 2008-01-06
US9480686B2 (en) 2016-11-01
US20130158044A1 (en) 2013-06-20
US20110152286A1 (en) 2011-06-23
US20180214444A1 (en) 2018-08-02
BRPI0609785B8 (pt) 2021-05-25
CY1111206T1 (el) 2015-06-11
IN2012DN00855A (de) 2015-07-10
US20170000786A1 (en) 2017-01-05
NL300946I2 (nl) 2018-09-26
US9206167B2 (en) 2015-12-08
USRE48059E1 (en) 2020-06-23
US20210113556A1 (en) 2021-04-22
SI1869025T1 (sl) 2011-04-29
US20100179322A1 (en) 2010-07-15
PL1869025T6 (pl) 2017-10-31
LUC00086I2 (de) 2018-11-26
US9839637B1 (en) 2017-12-12
US20190117648A1 (en) 2019-04-25
US20170231983A1 (en) 2017-08-17
EP1869025B1 (de) 2011-01-26
KR20080002817A (ko) 2008-01-04
HUE011611T6 (en) 2017-04-28
CN101155804A (zh) 2008-04-02
CY2018028I2 (el) 2019-07-10
AU2006237905A1 (en) 2006-10-26
EP1869025A1 (de) 2007-12-26
BRPI0609785B1 (pt) 2020-10-20
WO2006112464A1 (en) 2006-10-26
DK1869025T3 (da) 2011-04-04
AR053577A1 (es) 2007-05-09
ES2358631T7 (es) 2016-11-17
US8618109B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
HUS1800041I1 (hu) Piperazinnal helyettesített benzotiofének mentális rendellenességek kezelésére
HK1115341A1 (en) Composition for treating mental health disorders
HK1222537A1 (zh) 用於治療疾病或病症的液體製劑
IL185052A0 (en) Treatment of bone disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
EP1976377A4 (de) Verbindungen zur behandlung von stoffwechselstörungen
EP2278972A4 (de) Behandlung für neurologische und psychische erkrankungen
EP1983972A4 (de) Verbindungen zur behandlung von stoffwechselstörungen
ZA200803440B (en) Compounds for the treatment of metabolic disorders
IL198488A0 (en) Treatment of pervasive developmental disorders
IL195203A0 (en) Compounds for the treatment of metabolic disorders
IL192852A0 (en) Compounds for the treatment of metabolic disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0619218D0 (en) Treatment of conformational disorders
GB0512757D0 (en) Treatment of respiratory disorders